Atorvastatin Prevents Left Ventricular Remodeling in Spontaneously Hypertensive Rats

DOI Web Site 参考文献25件
  • Zhao Xiao-yan
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University
  • Li Ling
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University
  • Zhang Jin-ying
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University
  • Liu Gang-qiong
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University
  • Chen Ya-li
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University
  • Yang Pei-ling
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University
  • Liu Rui-yun
    Department of Cardiology, the First Affiliated Hospital, Zhengzhou University

書誌事項

公開日
2010
DOI
  • 10.1536/ihj.51.426
公開者
一般社団法人 インターナショナル・ハート・ジャーナル刊行会

この論文をさがす

説明

Statins improve left ventricular (LV) remodeling in spontaneously hypertensive rats (SHRs). This study was designed to investigate the effects of atorvastatin administered in the early stage on LV remodeling in SHRs, and to explore the underlying mechanisms.<br>Sixteen male 8-week-old SHRs were randomized to receive distilled water (SHR-DW) or atorvastatin (SHR-ATV) for 12 weeks. Age-matched male Wistar-Kyoto (WKY) rats gavaged with distilled water served as controls. LV remodeling was evaluated, myocardial CTGF expression levels were detected using Western blotting, and cardiomyocyte apoptosis was detected with the TUNEL method.<br>Compared with WKY and SHR-DW, atorvastatin treatment significantly decreased systolic blood pressure in SHRs; atorvastatin significantly inhibited LV remodeling, as indicated by the reduced LV weight/body weight ratio (SHR-ATV: 4.0 ± 0.4 versus SHR-DW: 4.7 ± 0.4 mg/g, P < 0.05), cardiomyocyte diameter (SHR-ATV: 16.2 ± 2.8 versus SHR-DW: 19.0 ± 1.0 μm, P < 0.05), and interstitial fibrosis (SHR-ATV: 3.3 ± 2.1 versus SHR-DW: 4.5 ± 1.8%, P < 0.05). Compared with WKY, myocardial CTGF expression was significantly increased and cardiomyocyte apoptosis decreased in SHRs. Compared with the SHR-DW group, atorvastatin treatment significantly inhibited myocardial CTGF expression (SHR-ATV: 0.69 ± 0.21 versus SHR-DW: 1.12 ± 0.27, P < 0.05) and induced cardiomyocyte apoptosis in SHRs (SHR-ATV: 5.2 ± 0.6 versus SHR-DW: 1.9 ± 0.3%, P < 0.05).<br>The results indicate that early-stage administration of atorvastatin effectively prevented LV remodeling in SHRs, and that inhibition of myocardial CTGF expression and induction of cardiomyocyte apoptosis may be the underlying mechanisms.

収録刊行物

  • International Heart Journal

    International Heart Journal 51 (6), 426-431, 2010

    一般社団法人 インターナショナル・ハート・ジャーナル刊行会

参考文献 (25)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ